TY  - GEN
AU  - Rhee,Jiyoung
AU  - Han,Sae-Won
AU  - Cha,Yongjun
AU  - Ham,Hye Seon
AU  - Kim,Hwang-phill
AU  - Oh,Do-Youn
AU  - Im,Seock-Ah
AU  - Park,Jong-Wan
AU  - Ro,Jungsil
AU  - Lee,Keun Seok
AU  - Park,In Hae
AU  - Im,Young-Hyuck
AU  - Bang,Yung-Jue
AU  - Kim,Tae-You
TI  - High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer
SN  - 1573-7217
PY  - 2011///0321
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Biomarkers, Tumor
KW  - blood
KW  - Breast Neoplasms
KW  - Capecitabine
KW  - Cell Line, Tumor
KW  - Cell Proliferation
KW  - drug effects
KW  - Chi-Square Distribution
KW  - Deoxycytidine
KW  - administration & dosage
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Drug Resistance, Neoplasm
KW  - Enzyme-Linked Immunosorbent Assay
KW  - Female
KW  - Fluorouracil
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Lapatinib
KW  - Logistic Models
KW  - Middle Aged
KW  - Quinazolines
KW  - Receptor, ErbB-2
KW  - metabolism
KW  - Republic of Korea
KW  - Risk Assessment
KW  - Risk Factors
KW  - Time Factors
KW  - Transforming Growth Factor alpha
KW  - Treatment Outcome
KW  - Up-Regulation
N1  - Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/s10549-010-1200-9
ER  -